Patenting Human Embryonic Stem Cells in the United States: The Legal and Ethical Debate
Janice M. Mueller
Chisum Patent Academy
CASRIP Newsletter, Vol. 14, No. 4, 2007
U. of Pittsburgh Legal Studies Research Paper Series
This article explores the legal and moral implications surrounding human embryonic stem cells (HESCs). Derived from human embryos that have been artificially fertilized but not yet implanted in a woman's uterus, HESCs are capable of giving rise to cells found in all tissues of the body. Public awareness of stem cell technology's enormous potential ignited in November 1998, when University of Wisconsin biologist Dr. James Thomson and his team announced that they had successfully isolated and cultured HESCs. The Wisconsin Alumni Research Foundation (WARF), the licensing arm of Dr. Thomson's employer, owns a broad portfolio of U.S. patents directed to the fruits of Thomson's work in primate/human embryonic stem cells. WARF contends that its patents "apply to all human embryonic stem cells in the United States." Despite WARF's policy of granting free licenses for academic research use of the patented cells, the patents' existence and their licensing and commercialization have proved controversial. As detailed in this article, the United States Patent and Trademark Office is currently reexamining three of WARF's fundamental patents on HESCs, signaling that substantial new questions exist concerning the patents' validity.
Number of Pages in PDF File: 9
Keywords: Patent law, human embryonic stem cells, HESCs, stem cell research, United States Patent and Trademark Office, USPTO, Wisconsin Alumni Research Foundation, WARF, Dr. James Thomson, morality
Date posted: June 5, 2009
© 2015 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo5 in 0.297 seconds